NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index; 13 of the 27 sources its claims cite were checked for support.
Abstract
Here we show that nicotinamide riboside kinase 1 (NRK1) is necessary and rate-limiting for the use of exogenous NR and NMN for NAD+ synthesis. Using stable isotope-labelled compounds, we confirm NMN is metabolized extracellularly to NR that is then taken up by the cell and converted into NAD+.
Overview
CoChat Summary
## TL;DR
NRK1 is the key rate-limiting enzyme that mammalian cells and liver require to convert exogenous nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) into NAD+. The paper shows that NMN is first dephosphorylated extracellularly to NR, which is then taken up and used for NAD+ synthesis.
## Key findings
- In NIH/3T3 cells, overexpression of active NRK1 or NRK2 converted NR-nonresponsive cells into NR-responsive cells, producing about a 4-fold increase in NAD+; catalytically inactive NRK1-D36A and NRK2-D35A did not.
- In F3T3-NRK1 cells, NR increased NAD+ at concentrations as low as 100 μM, with maximal effects at about 1 mM; NMN increased NAD+ only in NRK1-overexpressing cells and less potently than NR, while NAM worked regardless of NRK1.
- In primary hepatocytes from NRK1KO mice, NR and NMN failed to increase NAD+, whereas NA and NAM still increased NAD+ normally.
- In vivo, 500 mg kg−1 intraperitoneal NR raised liver NAD+ by about 220% in wild-type mice; NMN and NAM raised it by about 170%, and NR/NMN responses were significantly blunted in NRK1KO mice, though about 60% of the NR and NMN effect remained.
## Methods
- The study used gain- and loss-of-function models: transient and stable NRK1/NRK2 overexpression in cell lines, siRNA knockdown of Nmrk1 in AML12 hepatocytes, and a constitutive Nmrk1 knockout mouse.
- NAD+ precursor metabolism was tested in cultured cells, primary hepatocytes, primary brown adipocytes, and mice using NR, NMN, NAM, and NA treatments, plus isotope-labeled compounds for flux analysis.
- Main analyses included NAD+ quantification by assay, targeted LC-MS/LC-QqQ MS metabolomics, western blotting, and qPCR; statistical testing used t-tests or one-way ANOVA with Bonferroni post-test.
## Limitations
- The paper states that data are available only upon request, which limits immediate reproducibility access.
- The text makes evident that several mechanistic claims rely on high-dose precursor injections in mice (e.g., 500 mg kg−1 and 50 mg kg−1), so some in vivo effects may not reflect physiological exposure; this is evident from the text.
- The paper itself notes that future work is needed to better characterize circulating NAD+, NMN, and NR and to optimize organ-targeted formulations.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4 Extracellular NMN dephosphorylates to NR. HepG2 cells were treated with [18O]-labelled NR (a,b) or NMN (c,d). Intracellular enrichment of labelled compounds (a,c) and presence of labelled compounds in the media of treated cells (b,d). Results shown are mean±s.e.m. (n=3).](https://figures.cochat.ai/paper-figures/57e8a39cf3da45969cbff31a92059db8/nrk1-controls-nicotinamide-mononucleotide-and-nicotinamide-riboside-metabolism-figure-4.jpg)

![Figure 6 Extracellular conversion of NMN to NR by hepatocytes. (a) Primary hepatocytes were isolated from 10 to 15 weeks old WT mice. Cells were treated with 2 μM FK866 and ±2 mM CMP for 1 h. Then, 0.5 mM NR or NMN was added and NAD+ was measured after 2 h. (b,c) WT (b) and NRK1KO (c) hepatocytes were treated with [2H]-[13C]-double labelled NR or NMN. Intracellular enrichment of labelled compounds. Results shown are mean±s.e.m., **P<0.01 versus ctrl by two-sided unpaired T-test (n=3).](https://figures.cochat.ai/paper-figures/d72a2197ccbc48f5bcf199a67d302e52/nrk1-controls-nicotinamide-mononucleotide-and-nicotinamide-riboside-metabolism-figure-6.jpg)


Verification
Claims the paper makes
12 Valid · 1 Not valid · 12 Not checked · 97 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Whereas NMN concentration has been reported to reach around 50 μM in plasma14, our study and others13 have failed to detect comparable levels of circulating NMN.”
§ NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells > Discussion
What the sources say
- Not checked — no full text of the sourcecites [14] Revollo, J. R. et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab. 6, 363–375 (2007). source
- Supportedcites [13] Hara, N., Yamada, K., Shibata, T., Osago, H. & Tsuchiya, M. Nicotinamide phosphoribosyltransferase/visfatin does not catalyze nicotinamide mononucleotide formation in blood plasma. PLoS ONE 6, e22781 (2011). source
The Results section reports that NMN was not detected in freshly prepared mouse plasma by LC/MS/MS, with a detection limit of 50 nM—far below the approximately 50 µM level mentioned in the citing sentence. The Discussion likewise contrasts this nondetection with earlier reports of high plasma NMN concentrations. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In line with this, CD73 silencing blocks the use of NMN as an extracellular NAD+ precursor17.”
§ NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells > Discussion
What the sources say
- Partly supportedcites [17] Sociali, G. et al. Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model. Oncotarget 7, 2968–2984 (2015). sourceExperimental — accuracy not yet measured
The Results section (Figure 2D) reports that CD73 silencing reduced by 70% the ability of FK866-treated OVCAR-3 cells to generate intracellular NAD+ from extracellular NMN. This supports impaired use of NMN, but not the claim that silencing completely blocks it. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the induction of NRK2 in response to cellular damage or stress32 suggests the existence of a demand for circulating NR.”
§ NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells > Discussion
What the sources say
- Supportedcites [32] Sasaki, Y., Araki, T. & Milbrandt, J. Stimulation of nicotinamide adenine dinucleotide biosynthetic pathways delays axonal degeneration after axotomy. J. Neurosci. 26, 8484–8491 (2006). source
The Results section, “Expression of enzymes involved in NAD biosynthesis is induced in response to neuronal injury” (page not provided), reports that Nrk2 expression rose more than 20-fold after axotomy. The Discussion interprets this as part of the neuronal response to stress. The sentence’s suggestion of demand for circulating NR is the citing authors’ inference, not a finding it attributes to this source. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“This experiment, conducted in parallel with a human clinical trial at the same effective dose of NR, showed that NR produces the greatest rise in liver NAD+ synthesis, followed by NAM and NA24.”
§ NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells > Discussion
What the sources say
- Supportedcites [24] Trammell, S. A. et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat. Commun. 7, 12948 (2016). source
The Results section ('NR is the superior hepatic NAD+ precursor vitamin'; page not supplied) says the mouse dose was chosen to be comparable, after body-size adjustment, to an effective human NR dose, and that mice received NR or equimolar NAM and NA. The Discussion (page not supplied) ranks their effects on mouse liver NAD+ as NR, then NAM, then NA. The paper also reports a human clinical trial; it does not establish that the mouse experiment and trial ran at the same time. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, WT mice and NRK1/NRK2DKO displayed comparable increases in NAD+ levels in skeletal muscle after intraperitoneal NR and NMN administration (Supplementary Fig. 3d).”
§ NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells > Results > NRK1KO mice are deficient in NR and NMN utilization in vivo
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
50 more claims
Create a free account to see all 122 claims and every source verdict.
- Probably not a substantial claim. 25
- It may state two separate claims as one. 49
- Borderline: one of the tests for a substantial claim is unclear. 1
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Experimental evidence suggests that blood NA and NAM are able to cross the plasma membrane, while blood NAD+ cannot be taken up by cells directly but needs to be converted to smaller uncharged molecules to enter the cells (Hara et al., 2007; Ratajczak et al., 2016).”
From NAD+ in Brain Aging and Neurodegenerative Disorders (2019) · cites this paper as Ratajczak et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a previous study, the deficiency of NRK1, which phosphorylates NR to NMN, diminished the increase of NAD+ levels in the liver after oral NMN administration, suggesting that NMN was converted to NR before absorption (11).”
From Nicotinamide riboside and nicotinamide mononucleotide facilitate NAD + synthesis via enterohepatic circulation (2025) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Meanwhile, NR is converted to NMN by NR kinase (NRK), thereby bypassing the NAMPT-mediated step (11, 12).”
From Nicotinamide riboside and nicotinamide mononucleotide facilitate NAD + synthesis via enterohepatic circulation (2025) · cites this paper as [11]
In the citing paper
“Additionally, nicotinamide riboside (NR) integrates in this pathway via the conversion of NR into NMN by nicotinamide riboside kinase 1 (NRK1) or NRK2 (Bieganowski and Brenner, 2004; Ratajczak et al., 2016).”
From NAD+ in Brain Aging and Neurodegenerative Disorders (2019) · cites this paper as Ratajczak et al., 2016
Citations
Cites
HIGH-YIELD PREPARATION OF ISOLATED RAT LIVER PARENCHYMAL CELLS
Berry, M. N., & Friend, D. S. (1969) · The Journal of Cell Biology · doi:10.1083/jcb.43.3.506 · Cited by 4,424
Mammalian Sirtuins: Biological Insights and Disease Relevance
Haigis, M. C., & Sinclair, D. A. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092250 · Cited by 2,085 · cited 1×
“Importantly, sirtuin activation has been associated with an improvement in metabolic efficiency and healthspan in mammals 4,5 .”
Sirtuins as regulators of metabolism and healthspan
Houtkooper, R. H., Pirinen, E., & Auwerx, J. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3293 · Cited by 2,008
Self-citationCantó, C., Menzies, K. J., & Auwerx, J. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.05.023 · Cited by 1,648
Self-citationGomes, A. P., Price, N. L., Ling, A. J. Y., Moslehi, J. J., Montgomery, M. K., Rajman, L., White, J. P., Teodoro, J. S., Wrann, C. D., Hubbard, B. P., et al. (2013) · Cell · doi:10.1016/j.cell.2013.11.037 · Cited by 1,482
NAD+ and sirtuins in aging and disease
Imai, S.-I., & Guarente, L. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.04.002 · Cited by 1,481
Yoshino, J., Mills, K. F., Yoon, M. J., & Imai, S.-I. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.08.014 · Cited by 1,340
NAD + repletion improves mitochondrial and stem cell function and enhances life span in mice
Zhang, H., Ryu, D., Wu, Y., Gariani, K., Wang, X., Luan, P., D’Amico, D., Ropelle, E. R., Lutolf, M. P., Aebersold, R., et al. (2016) · Science · doi:10.1126/science.aaf2693 · Cited by 1,255
Self-citationCantó, C., Houtkooper, R. H., Pirinen, E., Youn, D. Y., Oosterveer, M. H., Cen, Y., Fernandez-Marcos, P. J., Yamamoto, H., Andreux, P. A., Cettour-Rose, P., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.04.022 · Cited by 1,238
Self-citationMouchiroud, L., Houtkooper, R. H., Moullan, N., Katsyuba, E., Ryu, D., Cantó, C., Mottis, A., Jo, Y.-S., Viswanathan, M., Schoonjans, K., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.016 · Cited by 1,210
Self-citation
Cited by
Items 301–365 of 365
Goorden, S. M. I., van Haaften–Visser, D. Y., Trętowicz, M. M., Bonte, R., Bogaerts, E., Jamal, Y., Vrieswijk, S., Huijser, E., Bökenkamp, R., van der Palen, R. L. F., et al. (2025) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2025.109194 · Cited by 4
Molecular physiological studies on health effects of dietary nicotinamide riboside, a vitamin B3
Shi, W. (2019) · doi:10.18174/471911 · Cited by 2
Escalante‐Covarrubias, Q., Mendoza-Viveros, L., González-Suárez, M., Becerril-Pérez, F., Pacheco-Bernal, I., Carreño‐Vázquez, E., Sanchez, P. B. M., Bustamante-Zepeda, M., Orozco-Solís, R., & Aguilar‐Arnal, L. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.12.503453 · Cited by 2
Hwang, E. S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-18722-3.00011-6 · Cited by 1
Obi, I. R., Sengupta, P., & Sabouri, N. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf853 · Cited by 3
“Nrk1 catalyzes the phosphorylation of niacinamide riboside (NR) to form niacinamide mononucleotide, a precursor for NAD + / NADH biosynthesis [ 94 , 95 ].”
Vitamin abnormalities in neuropathic corneal pain
Chow, B. J., Yu, M., Liu, C., Lee, I. X. Y., Tong, L. H. T., & Liu, Y. (2025) · Eye and Vision · doi:10.1186/s40662-025-00457-x · Cited by 1
“Current understanding suggests that the biosynthesis of NAD + via Vitamin B3 supplementation occurs in a three-step pathway, with nicotinic acid mononucleotide and nicotinic acid adenine dinucleotide as key intermediates [30, 44].”
Zhang, H., Ya, J., Liao, X., Du, X., Zhao, C., Ren, J., & Qu, X. (2025) · Small · doi:10.1002/smll.202509547 · Cited by 4
Attenuating Ischemia and Reperfusion Injury Using NAD+-Loaded Nanoparticles in Mouse Kidneys
Verhoven, B., Tong, Y., Chlebeck, P., Zhong, W., Zeng, W., Jennings, H., Miller, B., Heise, G., Levitsky, M., Xie, R., et al. (2025) · Transplantation Direct · doi:10.1097/txd.0000000000001890 · Cited by 1
“21 Furthermore, reports demonstrate that NAD + is routinely degraded extra-cellularly into its precursors before being carried into the cell 22 and, once inside the cell, precursors still need to be converted back to NAD + before they can afford full bioavailability.”
Sun, N., Cheng, X., Lu, L., Zhang, W., Li, K., Chen, Y., Li, Y., Liu, C., Zhang, Q., & Yin, P. (2026) · Journal of Food Biochemistry · doi:10.1155/jfbc/2506427 · Cited by 1
Stavrou, V., Ali, M., Gudgeon, N. H., Bishop, E. L., Fulton-Ward, T., Turley, B., Heising, S., Mohamed, S. H., Hain, S., George, L., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68863-w · Cited by 1
“Of note, NMNAT2, which is described to associate with Golgi apparatus/cytoplasm in other cells, was not detected, indicating NMNAT1 generates nuclear and cytoplasmic NAD in CD4 + T cells, and that capacity for this is increased upon activation (Fig.”
InfluentialVinten, K. T., Schomakers, B. V., Denis, S. W., van Weeghel, M., Jongejan, A., Ofman, R., Piersma, S. R., Jiménez, C. R., Janssens, G. E., Perez, R. Z., et al. (2026) · The FASEB Journal · doi:10.1096/fj.202501925r · Cited by 2
Green manufacturing synthesis of nicotinamide mononucleotide: Pathways, catalysts, and prospects
Peng, F., Ke, W., Jin, X., Xie, Y., Xue, Y., & Zhang, J.-F. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109683 · Cited by 1
Rumpler, M., van Mierlo, G., Vinten, K. T., Giner, M. P., Christen, S., Hayat, F., Makarov, M. V., Gardeux, V., Russeil, J., Schomakers, B. V., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-70965-4 · Cited by 1
“Instead, most NR was degraded to NAM and downstream metabolites, either in the gut 28 , or in circulation 29 .”
Self-citationLiu, J., Guo, X., Wang, N., Zhang, X., Wang, X., Li, G., Hou, X., Yu, L., Chen, Y., & Li, R. (2026) · Advanced Materials · doi:10.1002/adma.202519122 · Cited by 3
Skin Cancer Prevention and Antiaging: Role of Nicotinamide
Moro, F., Panebianco, A., Bartolocci, V., Capone, A., Guardo, A. D., Hyeraci, M., Gemma, G. P. A., Lella, G. D., Colonna, L., Ricci, F., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27114918 · Cited by 1
“However, in mammals, the predominant pathway for NR metabolism involves its phosphorylation to NMN by nicotinamide riboside kinases (NRKs) [17,18].”
Sarcopenia and satellite cell homeostasis disruption: the dual function of NAD+ metabolism
Li, C., Ai, Y., Yan, J., & Wu, S. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1803560 · Cited by 5
“(2) From nicotinamide riboside (NR): NR → NMN (via nicotinamide riboside kinase, NRK1/2) → NAD + (26, 29, 30).”
Prospects for Neuroprotective Therapies in Glaucoma: Drug Targets and Emerging Clinical Strategies
Rho, S., & Williams, P. A. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s612176 · Cited by 3
Potential significance of NAD+ biology translational research in super-aged Japan
山口慎太郎, 裕, 伊., & 純, 吉. (2020) · Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics · doi:10.3143/geriatrics.57.213 · Cited by 1
Braidy, N., & Sachdev, P. S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-823679-6.00005-9 · Cited by 1
Oakley, R. H., Campen, M. J., Paffett, M. L., Chen, X., Wang, Z., Parry, T. L., Hillhouse, C., Cidlowski, J. A., & Willis, M. S. (2018) · BMC Medical Genetics · doi:10.1186/s12881-018-0670-1 · Cited by 1
“Inositol hexakisphosphate kinase 3 (Ip6K3) has been linked to metabolism and lifespan in mice [36], while nicotinamide riboside kinase 2 (Nmrk2) has critical roles in NAD metabolism in mammalian cells [37].”
BackgroundCantó, C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-811752-1.00017-1 · Cited by 1
Self-citationNovel NAD+ metabolomic technologies and their applications to Nicotinamide Riboside interventions
Trammell, S. A. J., Wright, M. E., Piper, R. C., Brenner, C., Slusarski, D. C., & Wilson, M. E. (2016) · doi:10.17077/etd.mk206led · Cited by 1
Self-citationGray, E. L. (2019) · University of Birmingham Institutional Research Archive (University of Birmingham) · Cited by 1
Nicotinamide Adenine Dinucleotide (NAD+) in Aging
Braidy, N., Poljak, A., & Sachdev, P. S. (2019) · Springer eBooks · doi:10.1007/978-3-319-69892-2_1035-1 · Cited by 1
Connell, N. J. (2021) · Research Publications (Maastricht University) · doi:10.26481/dis.20210122nc · Cited by 1
Cordeiro, E. W. F. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.9.2021.tde-05082021-095853 · Cited by 1
TIR immune signaling is blocked by phosphorylation to maintain growth in plants and animalsPreprint
Li, J., Chen, S., Yu, B., Li, Q., Liu, R., Wang, Z., Wan, L., & Zhao, Y. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.09.647920 · Cited by 1
Axon Death Pathways Converge on Axed to Promote Axon Disassembly
Burdett, T. C. (2017) · The Journal of the American Medical Association (JAMA) Network (American Medical Association) · doi:10.13028/m2m89w
Vitamin B3 salvage and NAD\(^+\) metabolism in skeletal muscle
Fletcher, R. S. (2017) · University of Birmingham Institutional Research Archive (University of Birmingham)
Doig, C. L., Zielinska, A. E., Fletcher, R. S., Oakey, L. A., Elhassan, Y., Garten, A., Cartwright, D., Heising, S., Alsheri, A., Watson, D. G., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/567297
Understanding the Molecular Pathogenesis of Retinal Neurodegeneration
Lin, J. B. (2020) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/v6tn-2v15
“NR by nicotinamide riboside kinase 1 (NRK1) before it can be transported to the intracellular compartment (Ratajczak et al., 2016).”
Background子宮内膜癌細胞株における抗癌剤感受性の検討(子宮体部悪性腫瘍VI, 第57回日本産科婦人科学会学術講演会)
茂木, 真., 新美, 茂., 高倉, 聡., 柳田, 聡., 岡本, 愛., 落合, 和., & 田中, 忠. (2005) · 日本産科婦人科學會雜誌
Nicotinamide Adenine Dinucleotide (NAD+) in Aging
Braidy, N., Poljak, A., & Sachdev, P. S. (2021) · Springer eBooks · doi:10.1007/978-3-030-22009-9_1035
The Genomic Landscape of Pediatric Renal Cell CarcinomasPreprint
Beck, P., Selle, B., Madenach, L., Jones, D., Vokuhl, C., Gopisetty, A., Nabbi, A., Brecht, I. B., Ebinger, M., Wegert, J., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3974118
Damschroder, D., Perez, R. Z., Houtkooper, R. H., & Wessells, R. J. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.06.475267
Nutraceuticals for targeting NAD+ to restore mitochondrial function
Garten, A., & Lavery, G. G. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90256-4.00019-9
Metabolic precursors of nicotinamide adenine dinucleotide and the potential for their clinical use
Sutsko, I. P., Shlyahtun, A. H., & Semenenya, I. N. (2022) · Medical academic journal · doi:10.17816/maj89964
Qiu, S., Zhang, Y., Shao, S., Zhang, Y., Yin, J., Xu, X., Yang, L., Hong, Y., Yang, J. J., Tan, X., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3177159/v1
Li, Y., Tong, Y., Islam, Z. H., Zhang, K., Xie, R., Burger, J., Hoyt, N. E., Kent, E. W., Marcum, W. A., Johnston, C., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.20.581249
Metabolism and Receptor Mechanisms of Niacin Action
Boronovskiy, S. E., Сергеевна, К. В., & Nartsissov, Y. R. (2023) · Tsitologiya · doi:10.31857/s0041377123060032
The Fluorinated NAD Precursors Enhance FK866 Cytotoxicity by Activating SARM1 in Glioblastoma Cells
He, W. M., Yang, J. Y., Zhao, Z. Y., Xiao, W., Li, W. H., & Zhao, Y. J. (2024) · Biology · doi:10.3390/biology13090649
“NRKs, involved in an alternative salvage pathway of NAD synthesis, catalyze the formation of NMN from nicotinamide riboside (NR), representing a potential target for modulating NAD metabolism [11].”
BackgroundThe Application of Nicotinamide Coenzyme Precursors in Health Food
Feng, Z.-Y., She, J., Qin, Z., & Sheng, R. (2025) · Springer eBooks · doi:10.1007/978-981-97-9877-3_47
Identification, Source, and Intracellular Distribution of Nicotinamide Coenzyme I
Shen, J., Li, S., Liu, N., Huang, Q., Rui, Y., & Wang, Y. (2025) · Springer eBooks · doi:10.1007/978-981-97-9877-3_3
Liu, W., An, M., Wang, Q., Shang, Y., Zang, S., Ding, H., Fu, S., Liu, Y., Dong, X., Yang, X., et al. (2025) · Open Research (University of Surrey) · doi:10.1002/viw.20250139
Amino-Acid-mTORC1-Driven DDA1 Phosphorylation Promotes DNA Repair and Glioblastoma ProgressionPreprint
Peng, X., Chen, X., Wang, Z., An, Y., Liu, Y., Zhu, R., Li, L., Xu, D., Liu, R., Zhan, X., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7717041/v1
Thomas, S., Ben-Davies, R., Cetinkaya‐Fisgin, A., Hu, X., Li, X., Stewart, S., Pan, B., Twiss, J. L., Ratan, R. R., Willis, D. E., et al. (2026) · Journal of the Peripheral Nervous System · doi:10.1111/jns.70101 · Cited by 1
“Second, NR is converted to NAD + intracellularly [27] via NMN (Nicotinamide mononucleotide) which is the key metabolite that activates Sarm1 [28, 29].”
Nabil, H., Elkhwanky, M., Hassanen, M., Niskanen, E. A., Mysore, R., Palvimo, J. J., Kummu, O., & Hakkola, J. (2026) · Archives of Toxicology · doi:10.1007/s00204-025-04280-0 · Cited by 1
Cyclic-FMN Is a Detectable, Putative Intermediate of FAD Metabolism
Belfleur, L., Kallio, J. P., Richter, W., Gassman, N. R., Ziegler, M., & Migaud, M. E. (2026) · Biomolecules · doi:10.3390/biom16010175 · Cited by 1
Self-citationRenal aging: research models, interventions and development trends
An, Y., Li, R., Zhang, R., & Wu, G. G. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104626
Yu, Y., Zhong, X., Yu, X., Li, J., Liu, H., Liu, X., Jiang, L., & Nie, Z. (2026) · The Analyst · doi:10.1039/d5an01054c
Niacin Derivatives in MASLD: Metabolic and Therapeutic Insights
Rojo-López, M. I., Niño-Narvión, J., Antentas, M., Fernández‐Camins, B., Martínez-Rojo, E., Poca, M., Martínez‐Sánchez, M. A., Ramos‐Molina, B., Rossell, J., Mauricio, D., et al. (2026) · Nutrients · doi:10.3390/nu18060996
Cardoso, D. (2022) · theses.fr (ABES) · doi:10.70675/e5ce6d96z7253z4119zb119zc07f3977425d
Rôles du NAD dans la plasticité cellulaire cancéreuse
Gouasmi, R. (2025) · theses.fr (ABES) · doi:10.70675/4c8cef97z8e4fz4245z8588z8d740f2b17fe
Shimada, H., Shinohara, Y., Uto, Y., & Yamada, H. (2026) · Sensors · doi:10.3390/s26092714
“NR undergoes two sequential enzymatic transformations: phosphorylation to nicotinamide mononucleotide (NMN) via nicotinamide riboside kinase (NRK1–2) and conversion to NAD + through the action of NMN adenylyl-transferase (NMNAT1–3) [23].”
Nkrumah-Elie, Y. M., Kwon, J., Simpson, S., Idoine, R., Mavoyan, J. S., Russ, A., Cavanaugh, J., Hawkins, L., Fuller, K., Jaeger, J., et al. (2026) · medRxiv · doi:10.64898/2026.04.28.26352007 · Cited by 1
Amino-acids-mTORC1-driven DDA1 phosphorylation promotes DNA repair and glioblastoma progression
Chen, X., Wang, Z., An, Y., Liu, Y., Zhu, R., Li, L., Xu, D., Liu, R., Zhan, X., Yin, B., et al. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-03028-2
“Each experiment was repeated three times with similar results riboside to NMN in NAD ⁺ biosynthesis [56, 57]; ENO2, also known as neuron-specific enolase, which catalyzes the final step of glycolysis converting 2-phosphoglycerate to phosphoenolpyruvate [57, 58].”
Thoker, Z. A., Marwaha, L., & Prakash, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45380-9.00011-0
Tsurumi, K., Nomura, M., Ouchi, M., Yagishita, S., Kikuchi, N., Sato, T., Morita, M., Yamashita, Y., Hayashi, K., Soga, T., et al. (2026) · Cancer Science · doi:10.1111/cas.70486 · Cited by 1
Alcaraz, M., Ramachandra, R., Arnold, R., Teneche, M. G., Rajesh, A., Haddadin, L., Taing, M., Lei, X., Gandhi, A., Tzaridis, T., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.06.743365 · Cited by 1
Medoro, A., Davinelli, S., Mazzotta, C. G., Agnifili, L., & Scapagnini, G. (2026) · Pharmaceuticals · doi:10.3390/ph19081268 · Cited by 1
“NR and NMN carry a further constraint specific to this cell type: extracellular NMN must first be converted to NR for cellular uptake, and both precursors then depend on NRK1, whose transcripts are expressed at low levels in RGCs [36,67].”
Timbury, W., Gettings, S. M., Shek, R., Lindsay, C. D., Sharma, R., Najim, M., & Bourbia, N. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.11.735255
“…of nicotinamide adenine dinucleotide (NAD + ), which has neuroprotective properties against neurodegenerative diseases and axonal degeneration (Ratajczak et al. , 2016; Braidy et al. , 2019; Xie et al. , 2020; Amjad et al. , 2021; Covarrubias et al. , 2021; Icso & Thompson, 2022), and…”
Hou, W., Zhao, S., Kong, H., Gao, H., Luo, H., & Ye, H. (2026) · Marine Biotechnology · doi:10.1007/s10126-026-10692-5
Wang, X., Liu, C., Wang, J., Chen, F., Han, Z., Chen, X., Zheng, F., & Tian, X. (2026) · Life Sciences · doi:10.1016/j.lfs.2026.124684
Zhu, J., Li, J., Qin, Y., Cui, Y., & Mou, L. (2026) · Nutrition Reviews · doi:10.1093/nutrit/nuag128
Metadata
- Authors
- Ratajczak, J., Joffraud, M., Trammell, S. A. J., Ras, R., Canela, N., Boutant, M., Kulkarni, S. S., Rodrigues, M., Redpath, P., Migaud, M. E., Auwerx, J., Yanes, O., Brenner, C., & Cantó, C.
- Affiliations
- École Polytechnique Fédérale de Lausanne (CH)
- University of Iowa (US)
- Centre for Omic Sciences (ES)
- Queen's University Belfast (GB)
- Corresponding author
- Brenner, Charles
- Cantó, Carles
- ORCID
- Venue
- Nature Communications
- Published
- 2016-10-11
- Volume
- 7
- Issue
- 1
- Pages
- 13103-13103
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5476803
- OpenAlex
- W2531686927
- Cited by
- 378
- References
- 46
- Citations by year
- 2026: 34 · 2025: 35 · 2024: 48 · 2023: 46 · 2022: 38 · 2021: 40 · 2020: 31 · 2019: 43 · 2018: 28 · 2017: 31 · 2016: 2
- FWCI
- 19.91
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- Research Portal (Queen's University Belfast) (publishedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- Funders
- Roy J. Carver Charitable Trust
- École Polytechnique Fédérale de Lausanne
- National Institutes of Health
- Directorate for Biological Sciences
- Biotechnology and Biological Sciences Research Council (BB/N001842/1)
- National Institute on Alcohol Abuse and Alcoholism (R21AA022371)
- National Heart, Lung, and Blood Institute (R01HL108379)
- National Institute of General Medical Sciences (T32GM008629)
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Health Sciences › Nursing › Nutrition and Dietetics › Folate and B Vitamins Research
- Keywords
- nicotinamide mononucleotide, nicotinamide riboside, NAD+ synthesis, NAD+ precursors, sirtuins, poly(ADP-ribose) polymerase, NAD+ supplementation
- MeSH terms
- Animals, Humans, Injections, Intraperitoneal, Mammals, NAD, Niacinamide, Nicotinamide Mononucleotide, Pyridinium Compounds, Phosphotransferases (Alcohol Group Acceptor), Mice, Knockout, Hepatocytes, Hep G2 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.